01—Abstract
Summary
Summary of the 10-Q filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.
HCA Healthcare's third-quarter 2025 results were strong on the top and bottom lines.
Revenues rose 9.6% to $19.161 billiona (same-facility revenues up 9.2%), driven by a 6.1% increase in revenue per equivalent admission and a 3.2% increase in equivalent admissions. Net income attributable to HCA rose 29.4% to $1.643 billion, or $6.96 per diluted share, versus $4.88 a year earlier. Part of the margin improvement came from lower salaries and benefits as a share of revenue (43.6% vs. 45.0%) and a 23.9% effective tax rate.
Management attributed the revenue-per-admission gain partly to higher state supplemental Medicaid revenue from newly approved programs, a source of revenue the filing flags as exposed to federal policy changes. Cash flow and capital allocation were the main focus of the nine-month period. Operating cash flow rose to $10.277 billionb from $7.955 billion, but this was helped by a $1.259 billion decline in income taxes paid, related to an IRS deferral for Tennessee-based taxpayers until Q4 2025.
Management spent $7.509 billionc on share repurchases (21.3 million shares at an average of $352.40) and $3.455 billion on capital expenditures, against planned 2025 capex of about $5.0 billion. Cash fell to $997 million, and working capital turned negative at $(2.611) billion. Total debt rose to $44.511 billion, with $6.110 billion due within one year, including $1.910 billion of commercial paper.
Shareholders' deficit widened to $(2.159) billion. The filing also flags policy risks for 2026. The One Big Beautiful Bill Act is expected to reduce Medicaid spending and coverage, and sequestration could cut Medicare reimbursement by up to 4%d in early 2026 absent congressional action.
Medicaid DSH reductions of $8.0 billion per year began October 1, 2025, and the expiration of enhanced ACA premium tax credits after December 31, 2025 could raise uninsured volumes. Management states that cash flows and its credit facilities should be sufficient for liquidity needs.
02—Key points
Key Highlights
- Revenue grew 9.6% year over year to $19.161 billion in Q3 2025, with same-facility revenue up 9.2%, driven by a 6.1% rise in revenue per equivalent admission.
- Q3 diluted EPS was $6.96 versus $4.88 a year ago (up roughly 43%); net income attributable to HCA rose 29.4% to $1.643 billion.
- Salaries and benefits fell to 43.6% of revenue from 45.0%, supporting margin expansion; income before taxes rose 26.9% to $2.418 billion.
- Nine-month operating cash flow of $10.277 billion was boosted by a $1.259 billion reduction in tax payments, a timing benefit expected to reverse in Q4 2025.
- HCA repurchased $7.509 billion of stock in the nine months and retired 21.3 million shares; $3.256 billion remains under the January 2025 authorization.
- Total debt increased to $44.511 billion, with negative working capital of $2.611 billion and $6.110 billion due within one year; cash declined to $997 million.
- Policy exposure is elevated for 2026: possible Medicare sequestration cuts of up to 4%, $8.0 billion per year in Medicaid DSH reductions, and the scheduled expiration of enhanced ACA premium tax credits after 2025.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 30, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $19.16B$17.49B | +9.6% |
| Operating Expenses | $16.74B$15.58B | +7.5% |
| Interest Expense | $561.00M$515.00M | +8.9% |
| Net Income | $1.64B$1.27B | +29.4% |
| EPS (Basic) | $7.05$4.94 | +42.7% |
| EPS (Diluted) | $6.96$4.88 | +42.6% |
| Shares Outstanding (Basic) | 232.89M256.76M | −9.3% |
| Shares Outstanding (Diluted) | 236.18M259.92M | −9.1% |
05—Questions
Frequently Asked Questions
What drove the strong Q3 2025 earnings growth?
Growth came mainly from pricing and volume. Revenue per equivalent admission rose 6.1%, equivalent admissions rose 3.2%, and salaries and benefits fell as a percentage of revenue. Part of the pricing gain came from newly approved state supplemental Medicaid programs, which may be less durable given ongoing federal and state policy reviews.
Is HCA's operating cash flow improvement sustainable?
Only partly. Nine-month operating cash flow rose $2.322 billion, but about $1.259 billion of that came from deferred income tax payments for Tennessee-based taxpayers, which are due in Q4 2025. Excluding that timing benefit, the underlying improvement is smaller, though net income growth of about $811 million (excluding gains and losses on facility sales) also contributed.
How is HCA funding its share buybacks and capital spending while carrying high debt?
In the first nine months, HCA funded $7.509 billion of buybacks and $3.455 billion of capex largely through operating cash flow and net new borrowing of about $1.305 billion. It issued $5.250 billion of senior notes and established a $4.000 billion commercial paper program, which together increased short-term exposure. Management says operating cash flow, its $8.000 billion unsecured revolver, and debt market access are sufficient for expected liquidity needs.
What are the biggest regulatory risks to HCA's revenue outlook?
The main risks are reductions in Medicaid financing and supplemental payments under the OBBBA, a possible Medicare sequestration cut of up to 4% in early 2026, Medicaid DSH reductions of $8.0 billion per year starting October 1, 2025, and the expiration of enhanced ACA premium tax credits after 2025, which could increase uninsured volumes. The filing states that HCA cannot currently estimate the financial impact of changes to supplemental payment programs.
Are there any notable one-time items or tax effects in the quarter?
Yes. The Q3 2025 effective tax rate fell to 23.9% from 25.0%, mainly due to adjustments to unrecognized tax benefit liabilities. The IRS concluded its examination of the 2022 and 2023 returns with no material impact. Nine-month results also included $45 million of tax benefits from employee equity award settlements, compared with $93 million a year earlier, and a $4 million loss on facility sales, compared with a $209 million gain in 2024.
06—Continue